

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

**INFORMATION DISCLOSURE  
STATEMENT**

Docket Number:  
**11245/46604**

Application Number  
**09/374,028**

Filing Date  
**August 13, 1999**

Examiner  
**Jennifer Hunt**

Art Unit  
**1642**

JCEB7 U.S. PTO  
09/996954  
11/30/01

Invention Title  
**TREATMENT OF REFRACTORY HUMAN  
TUMORS WITH EPIDERMAL GROWTH FACTOR  
RECEPTOR ANTAGONISTS**


Inventor(s)  
**Harlan W. WAKSAL**

Address to:  
Assistant Commissioner for Patents  
Washington D.C. 20231

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97(c) and 1.98 and M.P.E.P. § 609, attorneys for Applicant hereby bring the references listed on the attached modified PTO Form No. 1449 to the attention of the Examiner. It is respectfully requested that the references be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
2. A copy of each patent, publication or other information listed on the modified PTO form 1449 is enclosed.
3. The Commissioner is hereby authorized to charge payment of the 37 C.F.R. §1.17(p) (submission of an information disclosure statement under §1.97(c)) fee of \$240.00 and any additional fees that may be required to the deposit account of Kenyon & Kenyon, deposit account number 11-0600. A duplicate of this sheet is enclosed.

Dated: November 30, 2001

By:

  
for Deborah A. Somerville 46,885  
(Reg. No. 31,995)

KENYON & KENYON  
One Broadway  
New York, N.Y. 10004  
(212) 425-7200 (telephone)  
(212) 425-5288 (facsimile)

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT PTO-1449</b>	ATTY. DOCKET NO. <b>11245/46604</b>	SERIAL NO. <b>09/374,028</b>
	APPLICANT <b>H. WAKSAL</b>	
	FILING DATE <b>August 13, 1999</b>	GROUP <b>1642</b>

JCS57 U.S. PTO  
 09/996954  
 11/20/01

**U. S. PATENT DOCUMENTS**

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE
	6,217,866	April 17, 2001	Schlessinger			
	5,891,996	April 6, 1999	Mateo de Acosta del Rio et al.			

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 00/31048	June 2, 2000	PCT				
	WO 98/33798	August 6, 1998	PCT				
	WO 97/42187	November 13, 1997	PCT				
	WO 97/30034	August 21, 1997	PCT				
	WO 97/27199	July 31, 1997	PCT				
	WO 96/33980	October 31, 1996	PCT				
	WO 96/30347	October 3, 1996	PCT				

**OTHER DOCUMENTS**

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
		Y. Han, et al. "Preferential Inhibition of Glioblastoma Cells with Wild-Type Epidermal Growth Factor Receptors by a Novel Tyrosine Kinase Inhibitor Ethyl-2,5-Dihydroxycinnamate", Oncology Research, vol. 9, 1997, pp. 581-587
		C.R. Divgi, et al. "Phase I and Imaging Trial of Indium 111-Labeled Anti-Epidermal Growth Factor Receptor Monoclonal Antibody 225 in Patients with Squamous Cell Lung Carcinoma", Journal of Nat'l Cancer Institute, vol. 83, no. 2, January 16, 1991, pp. 97-104
		A. B. Miller et al., "Reporting Results of Cancer Treatment", Cancer, vol. 47, no. 1, January 1, 1981, pp. 207-214
		Stedman's Medical Dictionary, 25 <sup>th</sup> Edition, p. 1338
		Pfister, et al., Abstract, 1667, 35 <sup>th</sup> Annual Meeting of ASCO, 1999
		Siu, et al., Abstract, 1498, 35 <sup>th</sup> Annual Meeting of ASCO, 1999

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609, draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	